Filing Flows › Foghorn Therapeutics (FHTX) › Guidance & outlook

Foghorn Therapeutics (FHTX) guidance and outlook

Foghorn Therapeutics' 10-Q filed Nov 9, 2026 makes 20 forward-looking statements.

Guidance and outlook

Forward-looking statements, 10-Q filed Nov 9, 2026

• We are a biology-first company, which means we focus first on the underlying genetics and biology of a disease relevant target and then leverage the most appropriate drugging approach to impact the disease biology.
• The Company expects to substantially complete the reduction in its workforce in the fourth quarter of 2026.
• Although we generated net income of $31.1 million for the nine months ended September 30, 2026, primarily as a result of deferred revenue recognized under our collaboration agreement with Lilly, we expect to continue to incur operating losses in future periods.
• Although we expect that our operating expenses and capital requirements will decrease in the near term as a result of our proprietary pipeline prioritization and the anticipated cost savings from the 2026 reduction in force, we expect that our expenses and capital requirements may increase in the future in connection with our ongoing activities, particularly if and as we:
• We will not generate revenue from product sales unless and until we successfully commercialize one of our product candidates, after completing clinical development and obtaining regulatory approval.
• If we obtain regulatory approval for any of our product candidates, we expect to incur significant expenses related to developing our commercialization capability to support product sales, marketing, manufacturing and distribution.
• Further, we expect to incur additional costs associated with operating as a public company.
• As a result, we will need substantial additional funding to support our continuing operations and pursue our growth strategy.
• Until we can generate significant revenue from product sales, if ever, we expect to finance our operations through a combination of equity offerings, debt financings and collaborations or licensing arrangements.
• Because of the numerous risks and uncertainties associated with pharmaceutical product development and the current geopolitical and economic and trade environment, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve or maintain profitability.
• To date, we have not generated any revenue from product sales and do not expect to do so in the near future.
• We expect that our research and development expenses may increase in the future as we advance our proprietary programs into clinical development and continue our discovery, research and preclinical activities in the near term and in the future.

Foghorn Therapeutics' latest quarter

Questions

What does Foghorn Therapeutics expect?

We are a biology-first company, which means we focus first on the underlying genetics and biology of a disease relevant target and then leverage the most appropriate drugging approach to impact the disease biology. The Company expects to substantially complete the reduction in its workforce in the fourth quarter of 2026. Although we generated net income of $31.1 million for the nine months ended September 30, 2026, primarily as a result of deferred revenue recognized under our collaboration agreement with Lilly, we expect to continue to incur operating losses in future periods.

Open the interactive view →

Updated Nov 9, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.